TLDR SpaceX’s latest tender offer prices shares at $421, valuing the company at approximately $800 billion Google parent Alphabet holds a stake from its 2015 investmentTLDR SpaceX’s latest tender offer prices shares at $421, valuing the company at approximately $800 billion Google parent Alphabet holds a stake from its 2015 investment

Alphabet (GOOGL) Stock: SpaceX Valuation Surge Means More Profits for Google

2025/12/15 20:37
3 min read

TLDR

  • SpaceX’s latest tender offer prices shares at $421, valuing the company at approximately $800 billion
  • Google parent Alphabet holds a stake from its 2015 investment when it joined a $1 billion funding round
  • Alphabet previously booked an $8 billion unrealized gain from SpaceX earlier in 2025
  • The higher SpaceX valuation will likely appear as another accounting gain in Alphabet’s Q4 earnings
  • Wall Street maintains a Strong Buy rating on GOOGL with upside potential ahead

Alphabet stands to benefit from a major jump in SpaceX’s private market valuation. The rocket company’s recent insider share sale valued the business at roughly $800 billion. Shares sold at $421 each in the tender offer.


GOOGL Stock Card
Alphabet Inc., GOOGL

This represents a huge leap from SpaceX’s previous $350 billion valuation from late 2024. For Alphabet, the increase means a higher carrying value for its investment stake. That translates to another potential earnings boost when the company reports results.

Google invested in SpaceX nearly a decade ago. In 2015, it partnered with Fidelity Investments on a $1 billion funding round. The two firms combined for about 10% of the space company at that time.

Alphabet keeps quiet about its current SpaceX ownership percentage. The company doesn’t disclose individual private investments by name in regulatory filings. But valuation changes at SpaceX have historically shown up in Alphabet’s quarterly results.

Previous SpaceX Gains Already Boosted Earnings

This isn’t the first time SpaceX has helped Alphabet’s bottom line. Back in April, the company reported an $8 billion unrealized gain from an investment in an unnamed private firm. Market observers widely understood this to be SpaceX.

That gain came after SpaceX’s late 2024 tender offer at the $350 billion valuation. The accounting boost helped Alphabet exceed Wall Street’s profit expectations for its March quarter. These types of gains show up as unrealized gains on non-marketable equity securities in financial statements.

The gains are paper profits rather than actual cash. But they still count toward reported net income for the quarter. When a private company’s value increases, Alphabet marks up its investment to reflect the new price.

What Investors Should Expect

With SpaceX now valued at $800 billion, the math suggests another substantial gain for Alphabet. Investors will get clarity when the company reports Q4 and full-year 2024 results in early February. Any increase in SpaceX’s carrying value should appear in those financials.

Alphabet’s core business remains focused on search advertising, YouTube, cloud services, and AI development. The SpaceX investment represents a side bet that’s delivered outsized returns. But it doesn’t change the company’s fundamental business model or growth drivers.

Analysts remain bullish on GOOGL shares. The stock holds a Strong Buy consensus rating with 29 Buy recommendations and seven Hold ratings. The average analyst price target of $323.64 implies modest upside from current trading levels.

Google declined to comment on its SpaceX holdings. Company policy prohibits discussing individual private investments. However, the updated valuation will become clear through required financial disclosures when Alphabet files its next quarterly report with regulators.

SpaceX continues expanding its Starlink satellite internet service and advancing rocket technology. The company’s valuation growth reflects strong business performance and investor demand for exposure to the space industry.

The post Alphabet (GOOGL) Stock: SpaceX Valuation Surge Means More Profits for Google appeared first on Blockonomi.

Market Opportunity
SURGE Logo
SURGE Price(SURGE)
$0.04309
$0.04309$0.04309
-10.34%
USD
SURGE (SURGE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26